Similar expression to FGF (SEF or IL17RD), is a tumor suppressor and an inhibitor of growth factors as well as of pro-inflammatory cytokine signaling. In this study, we examined the regulation of Sef expression by gonadotropins during ovarian folliculogenesis. In sexually immature mice, in situ hybridization (ISH) localized Sef gene expression to early developing oocytes and granulosa cells (GC) but not to theca cells. Sef was also expressed in mouse ovarian endothelial cells, in the fallopian tube epithelium as well as in adipose tissue venules. SEF protein expression, determined by immunohistochemistry (IHC), correlated well with Sef mRNA expression in GC, while differential expression was noticed in oocytes. High Sef mRNA but undetectable SEF protein levels were observed in the oocytes of primary/secondary follicles, while an inverse correlation was found in the oocytes of preantral and small antral follicles. Sef mRNA expression dropped after pregnant mare's serum gonadotropin (PMSG) administration, peaked at 6-8 h after human chorionic gonadotropin (hCG) treatment, and declined by 12 h after this treatment. ISH and IHC localized the changes to oocytes and mural GC following PMSG treatment, whereas Sef expression increased in mural GC and declined in granulosa-lutein cells upon hCG treatment. The ovarian expression of SEF was confirmed using human samples. ISH localized SEF transcripts to human GC of antral follicles but not to corpora lutea. Furthermore, SEF mRNA was detected in human GC recovered from preovulatory follicles. These results are the first to demonstrate Sef expression in a healthy ovary during folliculogenesis. Hormonal regulation of its expression suggests that Sef may be an important factor involved in intra-ovarian control mechanisms.
Introduction
Ovarian function is dependent on a complex coordination between the follicular somatic cells (granulosa and cumulus) and germ cells, mediated by endocrine and paracrine factors. Growth of antral follicles is stimulated by follicle-stimulating hormone (FSH) and insulin-like growth factor 1, and this can be modulated by a number of growth factors including members of the transforming growth factor beta, the fibroblast growth factor (FGF), and epidermal growth factor (EGF) families (Nilsson et al. 2001 , Parborell et al. 2001 , Mihm & Evans 2008 . Members of the FGF and EGF families, which act through receptor tyrosine kinases (RTK), have been found to be involved in various processes during follicular development. FGF2 stimulates proliferation and inhibits apoptosis of granulosa cells (GC; Gospodarowicz & Bialecki 1979 , Shikone et al. 1992 , Yamoto et al. 1993 , Vernon & Spicer 1994 , and also appears critical for luteal angiogenesis (Woad et al. 2009 ). FGF10 enhances cumulus expansion in cattle (Zhang et al. 2010 ) while FGF8 cooperates with BMP15 to promote glycolysis in cumulus cells, and induces oocyte nuclear maturation in mice (Sugiura et al. 2007) . EGF-like factors that are released from the GC in response to the preovulatory luteinizing hormone surge act through the EGF receptor on GC and cumulus cells to induce the expression of prostaglandin-endoperoxide sythase 2 (PTGS2) and other genes essential for oocyte maturation, cumulus expansion, follicle rupture and its luteinization (Shimada et al. 2006 , Hsieh et al. 2007 . Accordingly, EGF receptor null mice show reduced fertility and impaired ovulatory capacity (Hsieh et al. 2007) .
RTK activity is regulated in part by ligand binding to the extracellular domain, but also by association with intracellular negative feedback regulators. To date, three such antagonists have been identified: the Sprouty and the SPRED protein families, as well as similar expression to FGF (SEF; gene symbol IL17RD; , Guy et al. 2009 ). Among the Spry proteins, SPRY2 has been explored in the ovary, and its expression in GC is regulated by gonadotropins (Haimov-Kochman et al. 2005 , Sugiura et al. 2009 , Jiang et al. 2011 . Similar to the Sprouty and SPRED proteins, SEF antagonizes the activity of a number of RTKs, including the FGF and EGF receptors in mammals (Kovalenko et al. 2003 , Xiong et al. 2003 , Torii et al. 2004 , Yang et al. 2004 , Ziv et al. 2006 . However, contrary to Sprouty and SPRED proteins that are dedicated inhibitors of the MAP kinase (ERK/MAPK) pathway (Christofori 2003 , Dikic & Giordano 2003 , Guy et al. 2009 ), SEF modulates multiple signaling pathways including the inhibition of ERK/MAPK activation in response to various RTK ligands and suppression of FGF-mediated activation of AKT, a downstream effector of phosphatidylinositol 3-OH kinase (Kovalenko et al. 2003 , Ziv et al. 2006 . SEF also augments the activity of stress kinases (Yang et al. 2004 , Ziv et al. 2006 . Moreover, our recent study has expanded the inhibitory activity of SEF to include the pro-inflammatory cytokines interleukin 1 (IL1) and tumor necrosis factor (TNF), in which SEF interacts physically with the master transcription factor NFkB and inhibits its nuclear translocation upon cytokine stimulation (Fuchs et al. 2012) . Both TNF and IL1 have been implicated in various processes during follicular development (Williams & Erickson 2012) . Thus, the dual function of SEF distinguishes it from other RTK and NFkB inhibitors and furnishes SEF with the capacity to impact many physiological and pathological processes. Accordingly, and depending on cellular context, mammalian SEF orthologs can attenuate cell proliferation, differentiation, migration, or can induce apoptosis in response to growth factors (Kovalenko et al. 2003 , Xiong et al. 2003 , Torii et al. 2004 , Yang et al. 2004 , Darby et al. 2006 , Ziv et al. 2006 . Sef inactivation in mice induces inflammation in several organs (Tang et al. 2010 , http://www.mmrrc.org/strains/32387/032387.html).
Within the human reproductive system, SEF transcripts were detected in testes, ovarian surface epithelium (OSE), and mammary and prostate epithelium (Preger et al. 2004 , Zisman-Rozen et al. 2007 . SEF expression is downregulated in ovarian, breast and prostate carcinomas in a manner that correlates with tumor aggressiveness and poor prognosis, underscoring its role as a tumor suppressor (Darby et al. 2006 , Zisman-Rozen et al. 2007 , Murphy et al. 2010 . SEF inhibits FGF signaling also in cervical carcinoma and endometrial carcinoma cell lines (Torii et al. 2004 , Ziv et al. 2006 , Zisman-Rozen et al. 2007 , Zhang et al. 2011 . Thus far, SEF regulation in mammals was only demonstrated during wound healing in the model of rat nervous system (Grothe et al. 2008) , and nothing is known regarding SEF regulation in the reproductive system. The objectives of this study were to determine the cellular localization of SEF in the ovary and to investigate the hormonal regulation of SEF expression during advanced stages of folliculogenesis.
Materials and methods

Enzymes, hormones, reagents, and chemicals
Restriction enzymes and enzymes used in cDNA cloning and plasmid construction were from NEB (New England Biolab, Ipswich, MA, USA), Boehringer-Mannheim, Pharmacia, and Roche (Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany). Pregnant mare's serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG) were purchased from Chrono-gest Intervet (Boxmeer, The Nethelands) and Organon (Oss, The Netherlands) respectively. Blocking reagent, digoxigenin (DIG)-RNA labeling kit, 5-bromo-4-chloro-3-indolylphosphate, 4-toluidine salt, nitroblue tetrazolium chloride, maleic acid, T7 RNA polymerase, proteinase K, yeast tRNA, and anti-DIG (Fab) conjugated to alkaline phosphatase were from Roche. M-MLV reverse transcriptase and random hexamer primers were from Gibco-BRL. GVA-mounting solution, aminoethyl-carbazole solution, enzyme-conjugated HRPstreptavidin solution, antibody diluent reagent solution, serum-blocking solution, and biotinylated secondary antibody were from Zymed Labs (San Francisco, CA, USA). BSA was from ICN (MP Biomedicals, Aurora, Ohio, USA), and all other chemicals were from Sigma. Fluoromount-GTM was from Southern Biotechnology Associates, Inc. (Birmingham, Alabama, USA).
Generation of rodent-SEF antibody
RT-PCR was used to amplify a partial cDNA fragment encompassing residues 349-683 of rat SEF from rat brain RNA that shared 92.4% amino acid sequence identity with the mice protein. The first strand was synthesized using random hexamer primers, and amplification was performed using primers containing artificial BamHI site to facilitate cloning into pET3xa vector for bacterial expression ( (Studier et al. 1990) , 5 0 -GAGGATCCAGAGACAGGCTCCGGCCTCG-3 0 and 5 0 -GAGGATCCTTAGAGTCCTTCCATCAGAGGCA-3 0 ). The RT-PCR product was sub-cloned into A/T cloning vector and two independent clones were sequenced. For immunization, the amplification product was sub-cloned into the pET3xa vector. The recombinant protein fused in frame to the aminoterminal portion of Bacteriophage T7 q10 protein was produced from Escherichia coli strain BL21, and used for rabbit immunization as described previously . The resulting anti-serum recognized rat/mouse SEF by immunostaining (Immunohistochemistry (IHC)) of various tissues (to be published elsewhere), while no staining could be observed using preimmune serum, and signal was eliminated in the presence of excess immunogen (Fig. 2D ).
Animals and tissue collection
Sexually immature 25-day-old female C57BL/6 mice received s.c. injection of 10 IU PMSG (Chrono-gest Intervet) and their ovaries were collected after either 24 or 48 h. In another group of mice, PMSG administration was followed by the injection of hCG 48 h later (10 IU, i.p.). The ovaries were collected from this group of mice at different time intervals after hCG injection. Each treatment was performed on two mice per group. One ovary from each treated animal was taken for total RNA extraction and RT-PCR analysis, and the other was embedded in paraffin and used for IHC and mRNA in situ hybridization (ISH) analysis. The mice were killed and ovaries removed as described previously (Dekel & Sherizly 1983 
RT-PCR analysis of SEF and FGF7 transcripts
Total RNA was extracted from cells or tissues using TRIzol reagent to the manufacturer instructions. Equal amounts of RNA (1 mg) were used for the first-strand synthesis using M-MLV reverse transcriptase (Invitrogen) and random hexamer primers in a total volume of 20 ml. All PCR amplifications (25 cycles for GAPDH; 35 cycles for Sef and Fgf7) were carried out with ReddyMix reagent (Thermo Fisher Scientific, Wien, Austria) and the indicated primer pairs. The products were analyzed by gel electrophoresis on agarose gels and the intensity of bands were quantified using TINA Software (Raytest, Straubenhardt, Germany). The primers used for RT-PCR analysis include the following: mouse Sef (il17rd) common region (CR), forward, 5 0 -ACAGCAGCAGAAGGAAC-TACTTCC-3; reverse, 5 0 -CCTACATGCTGACTCTCCAGGTAT-3; hSEF CR, forward, 5 0 -AGCAAGTCAGGCCGGTCCCTATA-3; reverse, 5 0 -CAGACGAGTCATAGATGCCTGAGT-3; mSef isoform, forward, 5 0 -TTCACTGTCAACGCCTGTCTCA-3; reverse, 5 0 -TCAGGTTGTAACAACAGGTCACA-3; mSef-S isoform, forward, 5 0 -ACAGTTCTCTACACCATGTGTGT-3; reverse, 5 0 -TCAGGTTGTAACAACAGG-TCACA-3; mouse Fgf7, forward, 5 0 -TGGATACTGACACGGATCCTG-3; reverse, 5 0 -TGCCACAA-TTCCAACTGCCAC-3; mice Gapdh, forward, 5 0 -GAGTATGTCG-TGGAGTCTAC-3; reverse, 5 0 -TTGTCATGGATGACCTTGGC-3; and human GAPDH, forward, 5 0 -GGTGAAGGTCGGAGT-CAACGGA-3; reverse, 5 0 -GAGGGAT-CTCGCTCCTGGAAGA-3.
Isolation of human GC
The GC were collected from follicular fluids of healthy IVF patients during oocyte retrieval. All patients signed an informed consent for using the cells for research. According to the routine IVF protocol, the patients underwent hormonal treatment preceding the oocyte retrieval. As described previously (Barash et al. 2003) , this treatment started with a long midluteal phase suppression utilizing gonadotropin-releasing hormone agonist (Decapeptil; Ferring Pharmaceutical). Two weeks later, upon the achievement of pituitary suppression, gonadotropin administration was commenced. Recombinant FSH (Gonal-F, Serono SA) was started at a dose of 225 IU/day for 5 days and subsequently adjusted according to the individual response. When at least three follicles reached 18 mm in diameter, 250 mg hCG (Ovitrelle; Serono SA) was administrated. A transvaginal ultrasonographic guided follicle aspiration was performed 36 h following hCG administration. After removal of the oocytes for the IVF treatment, follicular fluids were centrifuged for 5 min at 400 g and the GC pellet was washed twice by resuspension in cold PBS followed by centrifugation. This protocol has been approved by the Kaplan Medical Center Review Board on the use of Human Subjects in Medical Research in accordance with the Helsinki Declaration and by the Israeli Ministry of Health in Jerusalem.
RNA ISH
For the detection of hSEF in ovary sections, we have used the probe and conditions described previously (Zisman-Rozen et al. 2007) . The probes used for the detection of mouse Sef transcripts were described elsewhere (Grothe et al. 2008) . The synthesis of DIG-labeled RNA probes, analysis of their specific activity, and ISH were carried out according to the manufacturer's instructions (Roche: In Situ Hybridization Application Manual). Paraffin-embedded sections (5 mm) were processed as described (Shaoul et al. 2006) except that deparaffinization was carried out using W-CAP reagent according to the manufacturer's instructions. Pre-hybridization (3 h, at 45 8C) and hybridization (16 h, at 42 8C) were carried out with the indicated DIG-labeled riboprobes. The sections were then washed (2! SSPE, 10 min, 24 8C and 0.2! SSPE, 1 h, 60 8C) and incubated (16 h, 24 8C) with anti-DIG (Fab) alkaline phosphatase-conjugated antibodies (1:2000). The sections were visualized using a Nikon eclipse E400 microscope. The sections, where indicated, were counterstained with Mayer's hematoxylin.
Immunohistochemistry
Paraffin-embedded tissue sections (5 mm) were subjected to immunostaining using the streptavidin-peroxidase technique according to the manufacturer's protocol (LAB-SA detection system, Zymed Labs). Endogenous peroxidase activity was blocked by incubating with 0.3% hydrogen peroxide in methanol (15 min, 24 8C). Antigen retrieval was carried out by incubation with 1 mg/ml trypsin at 37 8C for 25 min followed by incubation with blocking solution (1 h, 25 8C). Incubation with mSEF antibody (diluted 1:1500) was carried out for 2 h at RT. Color reaction was carried out using streptavidinperoxidase complex, with aminoethyl-carbazole solution as substrate. Mayer's hematoxylin was applied as counterstaining where indicated. Specific staining was determined by incubating ovary sections with blocking solution alone, pre-immune serum, or immune serum in the presence of rSEF recombinant protein used for the immunization. (Fig. 1A , B and C). Sef mRNA signal was highest in oocytes at early stages of follicular development (primary/secondary follicles, Fig. 1A , B and C). Mice theca cells were devoid of Sef mRNA (Figs 1B, C and 4A). The Sef transcripts were also readily observed in extrafollicular sites in the ovary, including endothelial cells of the blood vessels in the ovarian medulla ( Fig. 1D ) and in adipose tissue venules (Fig. 1F ). Similar to human SEF (Zisman-Rozen et al. 2007) , mSef transcripts were also present in the OSE (Fig. 1E ) and in the epithelial cells of the fallopian tube (Fig. 1G) . The adipose cells were negative for mSef expression (Fig. 1F) , as sections were incubated with sense probe (Fig. 1H) .
SEF protein was detected using a rabbit polyclonal antibody generated against rat SEF (see 'Materials and methods' section). With the exception of oocytes, the expression pattern of SEF protein, as determined by IHC, paralleled that of Sef mRNA (representative examples are shown in Fig. 2A, B and C) . In primary and secondary follicles, strong mRNA but no protein signal was observed in the oocytes, while this situation was reversed in the oocytes of preantral and small antral follicles (representative images are shown in Figs 1A , B, C and 2A, E, F). These observations were further confirmed by analyzing ovarian sections from four individual mice ( Fig. 2G and H) , indicating that high levels of mRNA were restricted predominantly to the oocytes of primary and secondary follicles, whereas protein staining was limited mainly to the oocytes of preantral and larger follicles. not observed in ovaries incubated with preimmune serum or when IHC was carried out in the presence of the SEF peptide used for immunization (Fig. 2D , and data not shown). Altogether, these results indicate that SEF is widely expressed in the ovary, and point to the possibility of differential regulation of Sef mRNA/SEF protein expression in the oocytes.
Hormonal regulation of SEF during follicular development
To examine whether SEF expression is regulated during follicular development, we initially employed RT-PCR using mSef-specific primers. RNA was extracted from the whole ovaries of immature female mice or mice treated with PMSG with or without hCG to trigger synchronous follicle maturation. In agreement with the RNA ISH of ovaries from immature mice, mSef transcript levels were high in the unstimulated ovaries. A relatively strong signal was apparent 24 h after PMSG treatment, followed by a decline in expression by 48 h after treatment (Fig. 3) . After hCG administration, mSef levels remain low for 2 h and gradually increased thereafter reaching a peak at 6-8 h, followed by a subsequent decline at 24 h after hCG treatment (Fig. 3) . Thus far, two isoforms have been described for mouse Il17rd: including msef, the zebrafish ortholog, and a shorter isoform (msef-S, (Rong et al. 2006) ).
To find out which isoform is induced upon hCG treatment we carried out RT-PCR analysis with primers from a region common to both isoforms and isoform-specific primers.
The analysis was carried out on RNA extracted from mouse testes, whole ovaries from control untreated mice, and mice treated with PMSG/hCG at a time point where Sef expression was maximal (8 h after hCG administration). mSef, but not mSef-S, was detected in untreated mice ovaries and is the isoform induced following hCG treatment. In agreement with results reported by others, mSef-S was detected in testes (Rong et al. 2006) . To identify the cellular compartment at which mSef expression was modulated during hormone-stimulated folliculogenesis, we performed mRNA ISH and IHC on ovary sections at different time points after PMSG and hCG treatment (ovaries from four mice per each time point). Changes in Sef mRNA and SEF protein expression were detected only in GC and oocytes. In agreement with the RT-PCR analysis, mSef mRNA and mSEF protein expression levels 24 h after PMSG remain relatively high as compared with the control untreated ovaries, while a significant reduction occurred 48 h after PMSG treatment (Fig. 4) . The reduction in Sef expression, however, was stage dependent. In small and medium antral follicles observed mainly at 24 h after PMSG treatment, SEF expression remained relatively uniform in both GC and the oocyte. Interestingly, the spatial organization of SEF expression was clearly altered in the GC of large antral follicles, where GC cells are spatially organized into cumulus cells surrounding the oocyte, periantral GC, and mural GC lining the follicular wall (Williams & Erickson 2012) . Sef mRNA/SEF protein levels were the highest in the cumulus cells compared with periantral GC, whereas mSef signal in the mural GC layers and the oocyte was hardly apparent (representative image is shown in Fig. 4F, insert) . Sef expression was also uniformly reduced in both the oocyte and GC in small follicles 48 h after PMSG treatment (Fig. 4D) . These findings corroborate the data of RT-PCR analysis and further localize the differential expression pattern of SEF during the antral stage of follicular development to the oocytes and GC. Ovulation in the superovulated mice occurs 8-12 h after hCG administration. At this stage, the cumulusoocyte complex is released from the ovary, and the mural GC differentiates to luteal cells which will form the corpus luteum (CL). Twenty-four hours after hCG administration, the majority of the ovarian tissue consists of corpora lutea. Six and eight hours after hCG administration, mSef expression in preovulatory follicles remained strong in the cumulus and was resumed in the mural GC (representative images are shown in Fig. 5A , D, G and J). Moreover, Sef mRNA and SEF protein continued to be expressed in the cumulus cells after ovulation (Fig. 5E) . Interestingly, Sef expression levels in GC of the small follicles were also increased as compared with the levels observed 48 h following PMSG administration (compare Fig. 5A to Fig. 4D ). By contrast, the expression of Sef mRNA and protein significantly decreased in the CL (Fig. 5B, C, F, H, I , K and L), while mRNA and protein levels remaining strong in luteal endothelial cells (Fig. 5F, K and L) . Similarly, mSef expression levels were not altered at 12 h after hCG treatment in GC of small follicles (e.g. Fig. 5H ), thereby demonstrating a differential spatial regulation of mSef in response to the preovulatory hormonal stimuli. The fluctuations in mSef expression in the GC lining the follicular wall (mural granulosa) following PMSG/hCG treatment suggested that signals emanating from the theca cells might regulate mSef expression in the underlying mural GC. One plausible candidate could be FGF7, which is specifically expressed in the theca while its receptor is expressed in GC (Parrott et al. 1994) . To examine this possibility, we determined the kinetics of Fgf7 mRNA expression by RT-PCR on RNA extracted from whole ovaries of untreated female mice or mice treated with PMSG alone or along with hCG. Similar to the situation with mSef (see Fig. 3 ), Fgf7 transcript levels were high in the unstimulated ovaries. The high levels of expression were sustained at 24 h after PMSG treatment and declined 48 h after treatment. The expression of Fgf7 was gradually increased from 2 h after hCG treatment, reaching a peak at 8 h (Fig. 6) . Thus, Fgf7 expression preceded mSef as would be expected from an inducer. Along this line, similar to mSef, Fgf7 expression decreased 12 h after hCG treatment (compare Fig. 3 with Fig. 6 ).
Expression of SEF mRNA in human ovarian follicles
To find out whether the data obtained in the mouse model is relevant to human, SEF mRNA expression was examined on normal human ovarian sections from two different individuals by RNA ISH. hSEF transcripts were also detected by a complementary RT-PCR analysis on GC collected from two patients undergoing IVF treatment. hSEF signal was detected in GC of large antral follicles as well as in theca interna but not in the theca externa, and was undetectable in the CL (representative images are shown in Fig. 7A and B) . Furthermore, SEF signal was observed in the GC cells collected from preovulatory follicles of the two donors undergoing IVF (Fig. 7C ). This expression in granulosa but not luteal cells is consistent with the data obtained in mice, supporting our findings that, similar to mouse Sef, human SEF is subjected to regulation during luteinization.
Discussion
Intra-ovarian somatic factors play essential roles during follicular development (Williams & Erickson 2012) . Regulation of somatic factors by negative feedback loops includes restriction of incoming cues following ligand-induced receptor activation or the stimulation of a counter regulatory mechanism interfering with the signal cascade (Niehrs & Meinhardt 2002) . With regard to ovarian folliculogenesis, little is known concerning the role of putative negative feedback mechanisms. In this study, we report for the first time that SEF is expressed in human GC cells but not in luteal cells. In the mouse ovary, Sef mRNA/SEF protein were present in GC at early stages of follicular development and their expression was spatially and temporally controlled throughout the gonadotropin-dependent phase of follicular development. Most interestingly, mSef/SEF protein expression was also differentially regulated in the oocytes during follicle development. These findings suggest the involvement of Sef in controlling various processes during follicular development. In growing follicles, GC proliferate extensively during the preantral stage, and are differentiated to distinct subpopulations depending on their positions relative to the oocyte. These differences are thought to be controlled by a morphogen-gradient emanating from the oocyte and become critically important as the follicle cells and oocyte prepared for ovulation (Williams & Erickson 2012) . While mSef is uniformly expressed in GC of follicles during early stages of development and during the preantral phase, extensive changes in its expression pattern/levels were observed during antral follicle growth. In the large antral follicles there was a gradient of Sef mRNA signal and immunoreactivity, being highest in cumulus cells and hardly detectable in the mural GC layer farthest from the oocyte. This apparent gradient in Sef expression pattern suggests that it may be involved in both the control of GC proliferation as well as regulation of their differentiation toward the development of the antral follicle.
mSef is likely to be involved in controlling subsequent stages of folliculogenesis because its expression was retained in cumulus cells during its expansion and throughout ovulation. The expression of mSef RNA/SEF protein was also resumed in GC cells lining the follicular wall in preovulatory follicles, suggesting that Sef expression might be controlled by signals emanating from the adjacent theca cells. FGF7, which is specifically expressed in the theca and acts on the underlying GC (Parrott et al. 1994) , might be a good candidate. The timing of Fgf7 expression during mouse follicular Expression was determined by ISH on normal human ovary paraffinembedded sections from two individuals, using a probe common to hSef isoforms (Zisman-Rozen et al. 2007) . GC and theca interna (TI) denote granulosa cells and TI respectively. Scale bar: 100 mm.
(C), RT-PCR was carried out with human SEF-specific primers on RNA extracted from GC cells collected from two females undergoing oocyte aspiration before IVF. Lanes 1 and 3, RT-PCR of RNA extracted from GC; lanes 2 and 4, first-strand synthesis was carried out in the absence of reverse transcriptase; PC, RT-PCR of RNA from human dermal fibroblasts which was used as positive control.
development (present study), which correlates with the changes observed in mSef expression in the mural GC as well as the previously described capacity of hSEF to regulate cellular responses to FGF7 (Ziv et al. 2006 , Zisman-Rozen et al. 2007 , support this notion. Following ovulation, mSef expression was switched off in the granulosa-lutein cells (GLC) in both mouse and human. These findings point to differential spatial regulation of SEF in GC during ovarian folliculogenesis. Our findings also point to differences in the mechanisms by which Sef expression is controlled in the oocytes and in the GC. In the latter, Sef mRNA and SEF protein expression coincided and their levels correlated, suggesting that in these cells Sef expression is regulated at the transcriptional level. The situation was different in the oocytes. At early stages of folliculogenesis, high mRNA signal but no SEF immunoreactivity was observed in oocytes, while the reverse situation was apparent in the fully-grown oocyte during the antral stage. SEF immunoreactivity was readily detected in the oocytes of preantral-to-medium antral follicles whereas Sef mRNA levels in these stages were very low as compared with those observed in the oocytes of primary/secondary follicles. One plausible explanation to this apparent discrepancy could be that Sef mRNA from earlier stages of folliculogenesis accumulates as stored mRNA in growing oocytes and is not translated until oocyte growth resumes; similar phenomena have been observed for other genes in mice and cattle (de Vantéry et al. 1997) . Our findings clearly indicate that in oocytes, Sef expression is regulated post transcriptionally, and further imply that Sef may participate in the acquisition of oocyte meiotic competence.
CL development is associated with dramatic tissue remodeling and is dependent on a well-orchestrated regulation of vascular out-growth and regression (Fraser & Wulff 2001) . This extensive tissue growth and vascularization is controlled by various differentiation and angiogenesis-promoting factors such as FGF2 (Stirling et al. 1991 , Yamamoto et al. 1997 , Reynolds et al. 2000 . This growth factor is abundant in small capillaries in the CL, where it can activate FGF-receptor signaling in the endothelial cells. The reported ability of SEF to regulate FGF2 action (Kovalenko et al. 2003 , Preger et al. 2004 , Ziv et al. 2006 , Zisman-Rozen et al. 2007 ) and the present finding that Sef expression is restricted to endothelial cells in the CL point to the existence of counter-regulatory mechanisms that prevent growth factor-induced SEF expression in the GLC. One such plausible mechanism might involve Spry2, which contrary to SEF is expressed in GLC in both human and rodent ovaries (Haimov-Kochman et al. 2005) . Interestingly, SEF and SPRY2 exhibit differential expression pattern also in oocytes, cumulus, and theca cells. Spry2 was not detected in the oocytes at any stage of follicular development in mice (Sugiura et al. 2009) , and cumulus cells in well-developed mouse antral follicles and human follicles were also negative for SPRY2 (Haimov-Kochman et al. 2005 , Sugiura et al. 2009 ). In addition, SEF is expressed in human but not rodent theca cells whereas Spry2 exhibits the opposite expression pattern being expressed in rodent but not human theca cells (Haimov-Kochman et al. 2005 , Sugiura et al. 2009 ). These observations might suggest a plausible antagonistic relationship between SEF and SPRY2, whereby SPRY2 is excluded from cells where SEF is expressed and viceversa during ovarian folliculogenesis. A negative regulatory dialog between these two proteins has been suggested during mouse brain development (Lin et al. 2005) . Alternatively, secreted factors may differentially regulate SPRY2 and SEF expression during folliculogenesis. Nevertheless, these findings suggest that SEF and SPRY2 regulate different stages of follicular development.
In summary, we have shown that Sef transcripts and SEF proteins are widely distributed in the ovary and demonstrated the complex mode of Sef mRNA/SEF protein regulation during ovarian folliculogenesis. This study supports a general function for SEF in the ovary as well as more specific effect during follicular development. As SEF is a pleotropic inhibitor, our novel findings add additional layers of complexity to the regulation of different compartments of the ovarian follicle by somatic and oocyte-derived signaling factors.
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